Standard Chartered Plc upped its guidance and announced a bigger-than-expected buyback as it reported fourth-quarter results against a backdrop of speculation around a possible takeover bid from the Middle East.
Credit Suisse Group AG is exiting distressed debt and special-situations trading, as part of its broader exit from risky and capital-intensive businesses.
The worst damage wrought by Russia’s campaign to destroy the Ukrainian energy grid is probably over because of improved air defense and Moscow’s deteriorating ability to strike, the head of the nation’s grid operator said.
Lenders including Natwest Group Plc, ING Groep NV, Bank of America Corp. and BNP Paribas SA are in the process of writing down about $300 million in loans to Eurovita after an Italian regulator suspended management and halted redemptions at the life insurer, people with knowledge of the matter said.
The head of French distiller Pernod Ricard SA expects further price increases in the second half of its fiscal year as inflation pressures persist and demand for its spirits including Jameson Irish whiskey normalizes in the US and China after the pandemic.
Commerzbank AG said it expects profits for this year to be significantly above the €1.4 billion euros ($1.5 billion) earned in 2022, as rising interest rates continue to hand European lenders their best results in years.
Binance, the world’s biggest crypto exchange, had earlier “gaps” in its regulatory compliance that have since been closed, Chief Strategy Officer Patrick Hillmann said in an interview.
Australian and Chinese officials will meet in the coming days to discuss a relaxation of trade restrictions after Commerce Minister Wang Wentao signaled that relations are set to improve further.
Bank Indonesia held its benchmark interest rate as cooling inflation and a stronger rupiah allowed a pause in one of Southeast Asia’s most aggressive tightening cycles post-pandemic.
AstraZeneca Plc’s Covid antibody drug was rejected by England’s cost regulator in a draft recommendation that said it’s unlikely to work against most circulating strains of the virus and is not cost-effective for the struggling National Health Service.
